CN106310219A - Compound oral solution with pholcodine - Google Patents
Compound oral solution with pholcodine Download PDFInfo
- Publication number
- CN106310219A CN106310219A CN201610709558.6A CN201610709558A CN106310219A CN 106310219 A CN106310219 A CN 106310219A CN 201610709558 A CN201610709558 A CN 201610709558A CN 106310219 A CN106310219 A CN 106310219A
- Authority
- CN
- China
- Prior art keywords
- parts
- pholcodine
- oral solution
- compound oral
- herba
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229960002808 pholcodine Drugs 0.000 title claims abstract description 48
- GPFAJKDEDBRFOS-FKQDBXSBSA-N pholcodine Chemical compound O([C@@H]1[C@]23CCN([C@H](C4)[C@@H]3C=C[C@@H]1O)C)C1=C2C4=CC=C1OCCN1CCOCC1 GPFAJKDEDBRFOS-FKQDBXSBSA-N 0.000 title claims abstract description 47
- 150000001875 compounds Chemical class 0.000 title claims abstract description 39
- 229940100688 oral solution Drugs 0.000 title claims abstract description 39
- 239000000284 extract Substances 0.000 claims abstract description 27
- 229940055416 blueberry extract Drugs 0.000 claims abstract description 25
- 235000019216 blueberry extract Nutrition 0.000 claims abstract description 25
- 235000019224 Camellia sinensis var Qingmao Nutrition 0.000 claims abstract description 23
- 238000000034 method Methods 0.000 claims abstract description 23
- 235000020339 pu-erh tea Nutrition 0.000 claims abstract description 23
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims abstract description 18
- WBWWGRHZICKQGZ-UHFFFAOYSA-N Taurocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCCS(O)(=O)=O)C)C1(C)C(O)C2 WBWWGRHZICKQGZ-UHFFFAOYSA-N 0.000 claims abstract description 18
- 239000010231 banlangen Substances 0.000 claims abstract description 18
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims abstract description 18
- 210000000582 semen Anatomy 0.000 claims abstract description 18
- 229940013618 stevioside Drugs 0.000 claims abstract description 18
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 claims abstract description 18
- 235000019202 steviosides Nutrition 0.000 claims abstract description 18
- WBWWGRHZICKQGZ-GIHLXUJPSA-N taurocholic acid Chemical compound C([C@@H]1C[C@H]2O)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@H](O)C1 WBWWGRHZICKQGZ-GIHLXUJPSA-N 0.000 claims abstract description 18
- CBEQULMOCCWAQT-WOJGMQOQSA-N triprolidine Chemical compound C1=CC(C)=CC=C1C(\C=1N=CC=CC=1)=C/CN1CCCC1 CBEQULMOCCWAQT-WOJGMQOQSA-N 0.000 claims abstract description 18
- 229960001128 triprolidine Drugs 0.000 claims abstract description 18
- 229960003180 glutathione Drugs 0.000 claims abstract description 17
- 239000002994 raw material Substances 0.000 claims abstract description 12
- 238000004519 manufacturing process Methods 0.000 claims description 19
- 241000746375 Andrographis Species 0.000 claims description 16
- 235000003969 glutathione Nutrition 0.000 claims description 16
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 14
- 238000001953 recrystallisation Methods 0.000 claims description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 11
- 238000010009 beating Methods 0.000 claims description 10
- 108090000526 Papain Proteins 0.000 claims description 7
- 239000004365 Protease Substances 0.000 claims description 7
- 240000000851 Vaccinium corymbosum Species 0.000 claims description 7
- 235000003095 Vaccinium corymbosum Nutrition 0.000 claims description 7
- 235000017537 Vaccinium myrtillus Nutrition 0.000 claims description 7
- 235000021014 blueberries Nutrition 0.000 claims description 7
- 238000000605 extraction Methods 0.000 claims description 7
- 238000004108 freeze drying Methods 0.000 claims description 7
- 229940055729 papain Drugs 0.000 claims description 7
- 235000019834 papain Nutrition 0.000 claims description 7
- 235000013616 tea Nutrition 0.000 claims description 7
- 238000000108 ultra-filtration Methods 0.000 claims description 7
- 238000002137 ultrasound extraction Methods 0.000 claims description 7
- 238000010298 pulverizing process Methods 0.000 claims description 6
- 238000002481 ethanol extraction Methods 0.000 claims description 2
- 244000269722 Thea sinensis Species 0.000 claims 1
- -1 pholcodine Compound Chemical class 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 15
- 238000005516 engineering process Methods 0.000 abstract description 4
- 240000007087 Apium graveolens Species 0.000 abstract description 2
- 235000015849 Apium graveolens Dulce Group Nutrition 0.000 abstract description 2
- 235000010591 Appio Nutrition 0.000 abstract description 2
- 244000118350 Andrographis paniculata Species 0.000 abstract 1
- 241000049464 Artemisia apiacea Species 0.000 abstract 1
- 235000011570 Artemisia caruifolia var apiacea Nutrition 0.000 abstract 1
- 206010059866 Drug resistance Diseases 0.000 abstract 1
- 108010024636 Glutathione Proteins 0.000 abstract 1
- 235000018142 Hedysarum alpinum var americanum Nutrition 0.000 abstract 1
- 240000006461 Hedysarum alpinum var. americanum Species 0.000 abstract 1
- 244000273928 Zingiber officinale Species 0.000 abstract 1
- 235000006886 Zingiber officinale Nutrition 0.000 abstract 1
- 235000008397 ginger Nutrition 0.000 abstract 1
- 235000012907 honey Nutrition 0.000 abstract 1
- 238000011031 large-scale manufacturing process Methods 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
- 238000010438 heat treatment Methods 0.000 description 14
- 238000002156 mixing Methods 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 239000003814 drug Substances 0.000 description 11
- 206010022000 influenza Diseases 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 206010011224 Cough Diseases 0.000 description 7
- 241001122767 Theaceae Species 0.000 description 6
- 238000007789 sealing Methods 0.000 description 5
- 206010019233 Headaches Diseases 0.000 description 4
- 239000003708 ampul Substances 0.000 description 4
- 231100000869 headache Toxicity 0.000 description 4
- DKSZLDSPXIWGFO-BLOJGBSASA-N (4r,4ar,7s,7ar,12bs)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;phosphoric acid;hydrate Chemical group O.OP(O)(O)=O.OP(O)(O)=O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC DKSZLDSPXIWGFO-BLOJGBSASA-N 0.000 description 3
- 230000000954 anitussive effect Effects 0.000 description 3
- 229960004415 codeine phosphate Drugs 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- YQSHYGCCYVPRDI-UHFFFAOYSA-N (4-propan-2-ylphenyl)methanamine Chemical compound CC(C)C1=CC=C(CN)C=C1 YQSHYGCCYVPRDI-UHFFFAOYSA-N 0.000 description 2
- 101100129915 Escherichia coli (strain K12) melB gene Proteins 0.000 description 2
- MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 description 2
- 206010028748 Nasal obstruction Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 230000001387 anti-histamine Effects 0.000 description 2
- 239000000739 antihistaminic agent Substances 0.000 description 2
- 239000003907 antipyretic analgesic agent Substances 0.000 description 2
- 229940124584 antitussives Drugs 0.000 description 2
- 229960001985 dextromethorphan Drugs 0.000 description 2
- 229960003782 dextromethorphan hydrobromide Drugs 0.000 description 2
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 206010028735 Nasal congestion Diseases 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000850 decongestant Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 208000010753 nasal discharge Diseases 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000004080 punching Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
- A61K35/644—Beeswax; Propolis; Royal jelly; Honey
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/19—Acanthaceae (Acanthus family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/19—Acanthaceae (Acanthus family)
- A61K36/195—Strobilanthes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/282—Artemisia, e.g. wormwood or sagebrush
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
- A61K36/315—Isatis, e.g. Dyer's woad
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/45—Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
- A61K36/725—Ziziphus, e.g. jujube
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9068—Zingiber, e.g. garden ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/35—Extraction with lipophilic solvents, e.g. Hexane or petrol ether
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Insects & Arthropods (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Husbandry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a compound oral solution containing pholcodine, prepared from, by weight, 4-6 arts of pholcodine, 6-8 parts of triprolidine, 2-4 parts of glutathione, 15-20 parts of radix isatidis, 5-12 parts of stevioside, 8-12 parts of artemisia apiacea, 4-10 parts of fresh ginger, 4-8 parts of andrographis paniculata, 4-8 parts of semen ziziphi spinosae, 2-6 parts of liquorice root, 1-2 parts of taurocholic acid, 2-4 parts of honey, 0.2-0.4 parts of Pu-erh tea extract, 0.2-0.4 parts of celery leaf extract, and 0.2-0.4 parts of blueberry extract; Compared with the prior technology, the compound oral solution has synergistic effect between the raw material components, the treatment effect is well with quick effect, the drug resistance is small, the medicinal safety is high, the side effect is small, the stability is good, the shelf life is long , which is easy to carry, the preparing process is simple, suitable for large-scale production and so on.
Description
Technical field
The present invention relates to medicines and health protection field, a kind of compound oral solution containing pholcodine.
Background technology
Flu, is the respiratory tract commonly encountered diseases caused by multiple virus, has higher sickness rate.The most practical controls
Treatment method is by antipyretic analgesic, subtracts nasal congestion agent, and the combination of antihistaminic and maincenter cough medicine alleviates flu disease
The heating that shape is caused by flu, headache, surrounding extremities aching pain, sneeze, watery nasal discharge, nasal obstruction, cough etc..
Maincenter cough medicine antitussive effect is powerful, and has the effect of slight sedation and analgesia；Antipyretic analgesic, at alleviating pain
While have effect of bringing down a fever；Decongestant, can alleviate nasal blockage symptom and alleviate cough；Antihistaminic, can alleviate sense
Allergic symptoms such as the sneeze in emitting, and this type of medicine has drowsiness feature, if the preparation taken containing this type of medicine at night is permissible
Patient is made to have reasonable sleep, can the preferably symptom such as fatigue alleviating.
It is codeine phosphate and dextromethorphan hydrobromide at the maincenter cough medicine that Application comparison on the market is many at present: phosphoric acid can
Treat because of have bigger additive, existing market repeatedly occurs the accident of abuse and by state food pharmaceuticals administration
The strict control of office；The antitussive of dextromethorphan hydrobromide is effective, but the untoward reaction example presented now gets more and more, and
Also substantial amounts of abuse event occur, the U.S. food Drug Administration moment pays close attention to the abuse condition of dextromethorphan, and sends
Do not abuse the warning of dextromethorphan.Pholcodine is also maincenter cough medicine, has the maincenter antitussive similar to codeine phosphate
Effect, also has calmness and analgesic activity, but additive weak compared with codeine phosphate, and neonate and child tolerate this medicine.And the suction of this medicine
Receiving fast elimination relatively slow, to reducing medicining times, safe medication has positive role.Therefore, be badly in need of developing a kind of toxic and side effects little,
Taking convenience, do not easily cause dependency, the novel compound oral solution containing pholcodine that mass effect is good.
Summary of the invention
It is an object of the invention to provide a kind of compound oral solution containing pholcodine, to solve in above-mentioned background technology
The problem proposed.
For achieving the above object, the present invention provides following technical scheme:
A kind of compound oral solution containing pholcodine, it is characterised in that according to the primary raw material of weight portion be: pholcodine 4-
6 parts, actidil 6-8 part, glutathion 2-4 part, Radix Isatidis 15-20 part, stevioside 5-12 part, Herba Artemisiae Annuae 8-12 part, life
Rhizoma Zingiberis Recens 4-10 part, Herba Andrographis 4-8 part, Semen Ziziphi Spinosae 4-8 part, Radix Glycyrrhizae 2-6 part, taurocholic acid 1-2 part, Mel 2-4 part, Folium camelliae assamicae extract
Thing 0.2-0.4 part, leaf of Herba Apii graveolentis extract 0.2-0.4 part, blueberry extract 0.2-0.4 part.
As the further scheme of the present invention: the described compound oral solution containing pholcodine, main according to weight portion
Raw material is: pholcodine 4.6-5.4 part, actidil 6-8 part, glutathion 2-4 part, Radix Isatidis 16-19 part, stevioside
7-10 part, Herba Artemisiae Annuae 9-11 part, Rhizoma Zingiberis Recens 5-9 part, Herba Andrographis 4-8 part, Semen Ziziphi Spinosae 4-8 part, Radix Glycyrrhizae 2-6 part, taurocholic acid 1-2 part,
Mel 2-4 part, Pu'er tea 0.2-0.4 part, leaf of Herba Apii graveolentis extract 0.2-0.4 part, blueberry extract 0.2-0.4 part.
As the further scheme of the present invention: the described compound oral solution containing pholcodine, main according to weight portion
Raw material is: pholcodine 5 parts, actidil 7 parts, glutathion 3 parts, Radix Isatidis 18 parts, stevioside 9 parts, Herba Artemisiae Annuae 10 parts,
7 parts of Rhizoma Zingiberis Recens, Herba Andrographis 6 parts, Semen Ziziphi Spinosae 6 parts, 4 parts of Radix Glycyrrhizae, taurocholic acid 2 parts, Mel 3 parts, Pu'er tea 0.3 part, celery
Dish leaf extract 0.3 part, blueberry extract 0.3 part.
As the further scheme of the present invention: the manufacture method of described Pu'er tea for drying rear powder by puerh tea leaves
Broken, then by soak with ethanol and ultrasonic extraction, last recrystallization gained.
As the further scheme of the present invention: the manufacture method of described leaf of Herba Apii graveolentis extract is dried also for being cleaned by leaf of Herba Apii graveolentis
Making beating, adds the laggard row ultrafiltration of Papain ferment treatment and is centrifuged, last recrystallization gained.
As the further scheme of the present invention: the manufacture method of described blueberry extract, for blue berry making beating being stirred evenly, uses
Ether carries out extraction vacuum-concentrcted, last lyophilization gained.
Wherein:
The preparation method of the compound oral solution containing pholcodine is as follows, by Radix Isatidis, stevioside, Herba Artemisiae Annuae, Rhizoma Zingiberis Recens, Herba Andrographis,
Semen Ziziphi Spinosae, Radix Glycyrrhizae carry out heating in water bath, heated and stirred 25-35min, heating-up temperature 35-42 DEG C；Heating in water bath is cooled to after terminating
Room temperature, adds taurocholic acid, Mel, Pu'er tea, leaf of Herba Apii graveolentis extract, blueberry extract and carries out whirlpool mixing, close
Envelope shading also carries out pasteurize, is subsequently added pholcodine, actidil and glutathion, filters i.e. to obtain contain after mixing
The compound oral solution of pholcodine.
Compared with prior art, the invention has the beneficial effects as follows:
The compound oral solution containing pholcodine prepared by the present invention, with the addition of plurality of Chinese composition, plays strengthening vital QI to eliminate pathogenic factors altogether, supports
Heart and tranquilizing mind, coordinate effects of internal organs negative and positive, improve human autoimmune's ability, for the treatment of flu etc. have determined curative effect,
The advantage that side effect is little, easy to use, and preparation technology of the present invention is simple, it is easy to industrialized production.
Detailed description of the invention
Below in conjunction with the embodiment of the present invention, the technical scheme in the embodiment of the present invention is clearly and completely described,
Obviously, described embodiment is only a part of embodiment of the present invention rather than whole embodiments.Based in the present invention
Embodiment, the every other embodiment that those of ordinary skill in the art are obtained under not making creative work premise, all
Belong to the scope of protection of the invention.
Embodiment 1
A kind of compound oral solution containing pholcodine, it is characterised in that according to the primary raw material of weight portion be: pholcodine 4
Part, actidil 6 parts, glutathion 2 parts, Radix Isatidis 15 parts, stevioside 5 parts, Herba Artemisiae Annuae 8 parts, 4 parts of Rhizoma Zingiberis Recens, Herba Andrographis 4
Part, Semen Ziziphi Spinosae 4 parts, 2 parts of Radix Glycyrrhizae, taurocholic acid 1 part, Mel 2 parts, Pu'er tea 0.2 part, leaf of Herba Apii graveolentis extract 0.2 part,
Blueberry extract 0.2 part；The manufacture method of described Pu'er tea is for pulverizing after being dried by puerh tea leaves, then is soaked by ethanol
Bubble and ultrasonic extraction, last recrystallization gained；The manufacture method of described leaf of Herba Apii graveolentis extract is dried also for being cleaned by leaf of Herba Apii graveolentis
Making beating, adds the laggard row ultrafiltration of Papain ferment treatment and is centrifuged, last recrystallization gained；The manufacture method of described blueberry extract
For blue berry making beating being stirred evenly, ether is used to carry out extraction vacuum-concentrcted, last lyophilization gained.
Wherein:
The preparation method of the compound oral solution containing pholcodine is as follows, by Radix Isatidis, stevioside, Herba Artemisiae Annuae, Rhizoma Zingiberis Recens, Herba Andrographis,
Semen Ziziphi Spinosae, Radix Glycyrrhizae carry out heating in water bath, heated and stirred 25min, heating-up temperature 35 DEG C；Heating in water bath is cooled to room temperature after terminating,
Add taurocholic acid, Mel, Pu'er tea, leaf of Herba Apii graveolentis extract, blueberry extract and carry out whirlpool mixing, sealing shading
And carry out pasteurize, it is subsequently added pholcodine, actidil and glutathion, after mixing, filters that i.e. obtain can containing Fu Er
Fixed compound oral solution.
Embodiment 2
A kind of compound oral solution containing pholcodine, it is characterised in that according to the primary raw material of weight portion be: pholcodine
4.6 parts, actidil 6 parts, glutathion 2 parts, Radix Isatidis 16 parts, stevioside 7 parts, Herba Artemisiae Annuae 9 parts, 5 parts of Rhizoma Zingiberis Recens, Herba Andrographis
4 parts, Semen Ziziphi Spinosae 4 parts, 2 parts of Radix Glycyrrhizae, taurocholic acid 1 part, Mel 2 parts, Pu'er tea 0.2 part, leaf of Herba Apii graveolentis extract 0.2
Part, blueberry extract 0.2 part；The manufacture method of described Pu'er tea is for pulverizing after being dried by puerh tea leaves, then passes through second
Alcohol soaks and ultrasonic extraction, last recrystallization gained；The manufacture method of described leaf of Herba Apii graveolentis extract is dried in the air for being cleaned by leaf of Herba Apii graveolentis
Dry doubling is pulled an oar, and adds the laggard row ultrafiltration of Papain ferment treatment and is centrifuged, last recrystallization gained；The making of described blueberry extract
Method, for blue berry making beating being stirred evenly, uses ether to carry out extraction vacuum-concentrcted, last lyophilization gained.
Wherein:
The preparation method of the compound oral solution containing pholcodine is as follows, by Radix Isatidis, stevioside, Herba Artemisiae Annuae, Rhizoma Zingiberis Recens, Herba Andrographis,
Semen Ziziphi Spinosae, Radix Glycyrrhizae carry out heating in water bath, heated and stirred 25min, heating-up temperature 35 DEG C；Heating in water bath is cooled to room temperature after terminating,
Add taurocholic acid, Mel, Pu'er tea, leaf of Herba Apii graveolentis extract, blueberry extract and carry out whirlpool mixing, sealing shading
And carry out pasteurize, it is subsequently added pholcodine, actidil and glutathion, after mixing, filters that i.e. obtain can containing Fu Er
Fixed compound oral solution.
Embodiment 3
A kind of compound oral solution containing pholcodine, it is characterised in that according to the primary raw material of weight portion be: pholcodine 5
Part, actidil 7 parts, glutathion 3 parts, Radix Isatidis 18 parts, stevioside 9 parts, Herba Artemisiae Annuae 10 parts, 7 parts of Rhizoma Zingiberis Recens, Herba Andrographis 6
Part, Semen Ziziphi Spinosae 6 parts, 4 parts of Radix Glycyrrhizae, taurocholic acid 2 parts, Mel 3 parts, Pu'er tea 0.3 part, leaf of Herba Apii graveolentis extract 0.3 part,
Blueberry extract 0.3 part；The manufacture method of described Pu'er tea is for pulverizing after being dried by puerh tea leaves, then is soaked by ethanol
Bubble and ultrasonic extraction, last recrystallization gained；The manufacture method of described leaf of Herba Apii graveolentis extract is dried also for being cleaned by leaf of Herba Apii graveolentis
Making beating, adds the laggard row ultrafiltration of Papain ferment treatment and is centrifuged, last recrystallization gained；The manufacture method of described blueberry extract
For blue berry making beating being stirred evenly, ether is used to carry out extraction vacuum-concentrcted, last lyophilization gained.
Wherein:
The preparation method of the compound oral solution containing pholcodine is as follows, by Radix Isatidis, stevioside, Herba Artemisiae Annuae, Rhizoma Zingiberis Recens, Herba Andrographis,
Semen Ziziphi Spinosae, Radix Glycyrrhizae carry out heating in water bath, heated and stirred 30min, heating-up temperature 39 DEG C；Heating in water bath is cooled to room temperature after terminating,
Add taurocholic acid, Mel, Pu'er tea, leaf of Herba Apii graveolentis extract, blueberry extract and carry out whirlpool mixing, sealing shading
And carry out pasteurize, it is subsequently added pholcodine, actidil and glutathion, after mixing, filters that i.e. obtain can containing Fu Er
Fixed compound oral solution.
Embodiment 4
A kind of compound oral solution containing pholcodine, it is characterised in that according to the primary raw material of weight portion be: pholcodine
5.4 parts, actidil 8 parts, glutathion 4 parts, Radix Isatidis 19 parts, stevioside 10 parts, Herba Artemisiae Annuae 11 parts, 9 parts of Rhizoma Zingiberis Recens, punching
8 parts of lotus, Semen Ziziphi Spinosae 8 parts, 6 parts of Radix Glycyrrhizae, taurocholic acid 2 parts, Mel 4 parts, Pu'er tea 0.4 part, leaf of Herba Apii graveolentis extract 0.4
Part, blueberry extract 0.4 part；The manufacture method of described Pu'er tea is for pulverizing after being dried by puerh tea leaves, then passes through second
Alcohol soaks and ultrasonic extraction, last recrystallization gained；The manufacture method of described leaf of Herba Apii graveolentis extract is dried in the air for being cleaned by leaf of Herba Apii graveolentis
Dry doubling is pulled an oar, and adds the laggard row ultrafiltration of Papain ferment treatment and is centrifuged, last recrystallization gained；The making of described blueberry extract
Method, for blue berry making beating being stirred evenly, uses ether to carry out extraction vacuum-concentrcted, last lyophilization gained.
Wherein:
The preparation method of the compound oral solution containing pholcodine is as follows, by Radix Isatidis, stevioside, Herba Artemisiae Annuae, Rhizoma Zingiberis Recens, Herba Andrographis,
Semen Ziziphi Spinosae, Radix Glycyrrhizae carry out heating in water bath, heated and stirred 35min, heating-up temperature 42 DEG C；Heating in water bath is cooled to room temperature after terminating,
Add taurocholic acid, Mel, Pu'er tea, leaf of Herba Apii graveolentis extract, blueberry extract and carry out whirlpool mixing, sealing shading
And carry out pasteurize, it is subsequently added pholcodine, actidil and glutathion, after mixing, filters that i.e. obtain can containing Fu Er
Fixed compound oral solution.
Embodiment 5
A kind of compound oral solution containing pholcodine, it is characterised in that according to the primary raw material of weight portion be: pholcodine 6
Part, actidil 8 parts, glutathion 4 parts, Radix Isatidis 20 parts, stevioside 12 parts, Herba Artemisiae Annuae 12 parts, 10 parts of Rhizoma Zingiberis Recens, Herba Andrographis
8 parts, Semen Ziziphi Spinosae 8 parts, 6 parts of Radix Glycyrrhizae, taurocholic acid 2 parts, Mel 4 parts, Pu'er tea 0.4 part, leaf of Herba Apii graveolentis extract 0.4
Part, blueberry extract 0.4 part；The manufacture method of described Pu'er tea is for pulverizing after being dried by puerh tea leaves, then passes through second
Alcohol soaks and ultrasonic extraction, last recrystallization gained；The manufacture method of described leaf of Herba Apii graveolentis extract is dried in the air for being cleaned by leaf of Herba Apii graveolentis
Dry doubling is pulled an oar, and adds the laggard row ultrafiltration of Papain ferment treatment and is centrifuged, last recrystallization gained；The making of described blueberry extract
Method, for blue berry making beating being stirred evenly, uses ether to carry out extraction vacuum-concentrcted, last lyophilization gained.
Wherein:
The preparation method of the compound oral solution containing pholcodine is as follows, by Radix Isatidis, stevioside, Herba Artemisiae Annuae, Rhizoma Zingiberis Recens, Herba Andrographis,
Semen Ziziphi Spinosae, Radix Glycyrrhizae carry out heating in water bath, heated and stirred 35min, heating-up temperature 42 DEG C；Heating in water bath is cooled to room temperature after terminating,
Add taurocholic acid, Mel, Pu'er tea, leaf of Herba Apii graveolentis extract, blueberry extract and carry out whirlpool mixing, sealing shading
And carry out pasteurize, it is subsequently added pholcodine, actidil and glutathion, after mixing, filters that i.e. obtain can containing Fu Er
Fixed compound oral solution.
Clinical trial:
(1) 200 example influenza patients are carried out clinical treatment close wipe the sweat, age 6-60 year, 32 years old mean age.
(2) Therapeutic Method: with the compound oral solution that embodiment 2 is made, take night and morning every day, ampoule
10ml, 5 days courses for the treatment of, after taking substantially 1 day takes effect, and within 2-3 days, cures, Rehabilitation；Clinical treatment 200 example, wherein, cures
198 examples, effective 2 examples, invalid 0 example, total effective rate is 100%.
(3) model case:
Wang, 11 years old, female, suffer from influenza, generate heat, have a headache and with cough, take the compound oral solution of the present invention
One day twice, ampoule 10ml, 1 day takes effect, and within 2 days, cures；
Grandson, 34 years old, man, suffer from influenza, severe heating, headache, pharyngalgia, take the compound oral solution one of the present invention
It twice, ampoule 10ml, 1 day takes effect, and within 3 days, cures；
Chen, 52 years old, female, suffer from viral influenza, severe is generated heat, is had a headache and with bronchitis, takes the compound recipe of the present invention
Oral administration solution one day twice, ampoule 10ml, 2 days take effect, and within 3 days, cure.
It is obvious to a person skilled in the art that the invention is not restricted to the details of above-mentioned one exemplary embodiment, Er Qie
In the case of the spirit or essential attributes of the present invention, it is possible to realize the present invention in other specific forms.Therefore, no matter
From the point of view of which point, all should regard embodiment as exemplary, and be nonrestrictive, the scope of the present invention is by appended power
Profit requires rather than described above limits, it is intended that all by fall in the implication of equivalency and scope of claim
Change is included in the present invention.
Although moreover, it will be appreciated that this specification is been described by according to embodiment, but the most each embodiment only wraps
Containing an independent technical scheme, this narrating mode of description is only that for clarity sake those skilled in the art should
Description can also be formed those skilled in the art through appropriately combined as an entirety, the technical scheme in each embodiment
May be appreciated other embodiments.
Claims (6)
1. the compound oral solution containing pholcodine, it is characterised in that according to the primary raw material of weight portion be: pholcodine
4-6 part, actidil 6-8 part, glutathion 2-4 part, Radix Isatidis 15-20 part, stevioside 5-12 part, Herba Artemisiae Annuae 8-12 part,
Rhizoma Zingiberis Recens 4-10 part, Herba Andrographis 4-8 part, Semen Ziziphi Spinosae 4-8 part, Radix Glycyrrhizae 2-6 part, taurocholic acid 1-2 part, Mel 2-4 part, Folium camelliae assamicae carry
Take thing 0.2-0.4 part, leaf of Herba Apii graveolentis extract 0.2-0.4 part, blueberry extract 0.2-0.4 part.
Compound oral solution containing pholcodine the most according to claim 1, it is characterised in that described containing pholcodine
Compound oral solution, according to the primary raw material of weight portion be: pholcodine 4.6-5.4 part, actidil 6-8 part, paddy Guang
Sweet peptide 2-4 part, Radix Isatidis 16-19 part, stevioside 7-10 part, Herba Artemisiae Annuae 9-11 part, Rhizoma Zingiberis Recens 5-9 part, Herba Andrographis 4-8 part, Semen Ziziphi Spinosae
4-8 part, Radix Glycyrrhizae 2-6 part, taurocholic acid 1-2 part, Mel 2-4 part, Pu'er tea 0.2-0.4 part, leaf of Herba Apii graveolentis extract
0.2-0.4 part, blueberry extract 0.2-0.4 part.
Compound oral solution containing pholcodine the most according to claim 1 and 2, it is characterised in that described can containing Fu Er
Fixed compound oral solution, according to the primary raw material of weight portion be: pholcodine 5 parts, actidil 7 parts, glutathion 3
Part, Radix Isatidis 18 parts, stevioside 9 parts, Herba Artemisiae Annuae 10 parts, 7 parts of Rhizoma Zingiberis Recens, Herba Andrographis 6 parts, Semen Ziziphi Spinosae 6 parts, 4 parts of Radix Glycyrrhizae, taurocholic acid
2 parts, Mel 3 parts, Pu'er tea 0.3 part, leaf of Herba Apii graveolentis extract 0.3 part, blueberry extract 0.3 part.
Compound oral solution containing pholcodine the most according to claim 3, it is characterised in that described Pu'er tea
Manufacture method for pulverizing after puerh tea leaves is dried, then by soak with ethanol and ultrasonic extraction, last recrystallization gained.
Compound oral solution containing pholcodine the most according to claim 3, it is characterised in that described leaf of Herba Apii graveolentis extract
Manufacture method for by leaf of Herba Apii graveolentis clean dry and pull an oar, add the laggard row ultrafiltration of Papain ferment treatment be centrifuged, the most heavily tie
Brilliant gained.
Compound oral solution containing pholcodine the most according to claim 3, it is characterised in that described blueberry extract
Manufacture method, for blue berry making beating being stirred evenly, uses ether to carry out extraction vacuum-concentrcted, last lyophilization gained.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610709558.6A CN106310219A (en) | 2016-08-24 | 2016-08-24 | Compound oral solution with pholcodine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610709558.6A CN106310219A (en) | 2016-08-24 | 2016-08-24 | Compound oral solution with pholcodine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106310219A true CN106310219A (en) | 2017-01-11 |
Family
ID=57742017
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610709558.6A Pending CN106310219A (en) | 2016-08-24 | 2016-08-24 | Compound oral solution with pholcodine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106310219A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107483397A (en) * | 2017-06-19 | 2017-12-15 | 上海高顿教育培训有限公司 | A kind of examinee's self-test assessment method based on B/S framework |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101716344A (en) * | 2009-11-13 | 2010-06-02 | 宜昌人福药业有限责任公司 | Pholcodine-containing compound pharmaceutical preparation for treating cold |
| CN202052473U (en) * | 2011-04-22 | 2011-11-30 | 南昌立健药业有限公司 | Micro-filtration membrane device for filtering and refining compound traditional Chinese medicinal oral solution |
-
2016
- 2016-08-24 CN CN201610709558.6A patent/CN106310219A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101716344A (en) * | 2009-11-13 | 2010-06-02 | 宜昌人福药业有限责任公司 | Pholcodine-containing compound pharmaceutical preparation for treating cold |
| CN202052473U (en) * | 2011-04-22 | 2011-11-30 | 南昌立健药业有限公司 | Micro-filtration membrane device for filtering and refining compound traditional Chinese medicinal oral solution |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107483397A (en) * | 2017-06-19 | 2017-12-15 | 上海高顿教育培训有限公司 | A kind of examinee's self-test assessment method based on B/S framework |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101543594B (en) | Mulberry-chrysanthemum oral liquid | |
| CN105412858A (en) | Syrup and preparation method thereof | |
| CN105326888A (en) | Medicinal composition for treating child phlegm-heat obstructing lung type asthma | |
| CN109718286A (en) | For treating external application type Traditional Chinese medicine composition patch, preparation and its application of fever | |
| CN105582089A (en) | Composition for preventing and treating pediatric skin diseases and preparation method of composition | |
| CN102139051B (en) | Application of soft capsule capable of clearing heat and eliminating toxin in preparation of medicament for treating viral pneumonia | |
| CN104248722A (en) | Medicament for treating female hypersexuality | |
| CN104147063A (en) | Compound pediatric antipyretic suppository and preparation method thereof | |
| CN103960542B (en) | A kind of feed for preventing and treating swine eperythrozoonosis and Chinese medicine composition | |
| CN106310219A (en) | Compound oral solution with pholcodine | |
| CN103142987B (en) | Medicament for treating mumps | |
| CN102397533B (en) | Compound propolis composition for treating livestock egg drop syndrome and preparation method thereof | |
| CN103028041B (en) | Traditional Chinese medicine composition for treating acute nasosinusitis of children and preparation method of traditional Chinese medicine composition | |
| CN106177156A (en) | A kind of Chinese medicine composition preventing and treating infectious bovine rhinotrachetis and application thereof | |
| CN102106999A (en) | Chinese medicinal compound preparation for treating dysphagia due to stroke and preparation method thereof | |
| CN101181448A (en) | Oral administration proprietary Chinese medicine for curing facial palsy | |
| CN102727589B (en) | Medicament for treating cough with lung heat of children | |
| CN107095977A (en) | A kind of medicament and its pharmaceutical formulation and preparation method with the malicious effect of fire row of dispelling | |
| CN107773581A (en) | A kind of silver yellow Neulized inhalation pharmaceutical solutions and preparation method thereof | |
| CN107050395B (en) | Traditional Chinese medicine sigmoid colon instillation preparation for treating infantile exogenous fever and preparation method and application thereof | |
| CN106237070A (en) | A kind of Chinese medicine oral liquid for treating the airsacculitis that chicken mixed infection causes | |
| CN105168821A (en) | Cough-relieving traditional Chinese medicine composition and preparation method thereof | |
| CN105641655A (en) | Traditional Chinese medicine composition for preventing foot-and-mouth disease and preparing method and application thereof | |
| CN104888179A (en) | Traditional Chinese medicine capsule for treating wind-cold and preparation method of traditional Chinese medicine capsule | |
| CN108434236A (en) | A kind of Chinese medicine composition for treating cat fever |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170111 |